NC762

NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4) . NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors[1].

12352203

TNF Receptor; Transmembrane Glycoprotein

Apoptosis; Immunology/Inflammation

Cancer-programmed cell death

Cancer

[1]Myint, Han, et al. "748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors." (2022) .|[2]Kristina Archer, et al. Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies. Cancer Res 1 July 2021; 81 (13_Supplement) : 3193.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991223/

Inhibitory Antibodies

Phase 2